Short Interest in Ensysce Biosciences, Inc. (NASDAQ:ENSC) Increases By 85.7%

Ensysce Biosciences, Inc. (NASDAQ:ENSCGet Free Report) was the recipient of a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 84,700 shares, a growth of 85.7% from the December 15th total of 45,600 shares. Based on an average daily volume of 1,800,000 shares, the short-interest ratio is currently 0.0 days.

Institutional Trading of Ensysce Biosciences

An institutional investor recently bought a new stake in Ensysce Biosciences stock. Anson Funds Management LP acquired a new stake in shares of Ensysce Biosciences, Inc. (NASDAQ:ENSCFree Report) in the third quarter, according to the company in its most recent filing with the SEC. The firm acquired 983,518 shares of the company’s stock, valued at approximately $236,000. Anson Funds Management LP owned about 11.15% of Ensysce Biosciences as of its most recent filing with the SEC. Hedge funds and other institutional investors own 5.63% of the company’s stock.

Ensysce Biosciences Price Performance

Shares of ENSC stock traded down $0.42 on Tuesday, hitting $6.75. 52,040 shares of the stock traded hands, compared to its average volume of 58,199. Ensysce Biosciences has a 52 week low of $2.12 and a 52 week high of $30.90. The firm has a 50 day simple moving average of $8.28 and a two-hundred day simple moving average of $6.61. The firm has a market cap of $8.82 million, a price-to-earnings ratio of -0.25 and a beta of 0.55.

Ensysce Biosciences (NASDAQ:ENSCGet Free Report) last posted its earnings results on Tuesday, November 12th. The company reported $1.05 earnings per share for the quarter, beating the consensus estimate of ($4.50) by $5.55. Ensysce Biosciences had a negative net margin of 179.26% and a negative return on equity of 292.81%. The company had revenue of $3.42 million during the quarter, compared to analysts’ expectations of $0.25 million. Sell-side analysts forecast that Ensysce Biosciences will post -12.44 EPS for the current year.

Ensysce Biosciences Company Profile

(Get Free Report)

Ensysce Biosciences, Inc, a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.

Read More

Receive News & Ratings for Ensysce Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ensysce Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.